Phase 1/2a
Arrowhead’s RNAi Obesity Programs ARO-INHBE and ARO-ALK7 Advance with Encouraging Phase 1/2a Data
Arrowhead Pharmaceuticals; ARO-INHBE; ARO-ALK7; RNAi; obesity; Phase 1/2a; tirzepatide; Zepbound; weight loss
Actionable Insights Powered by AI
Arrowhead Pharmaceuticals; ARO-INHBE; ARO-ALK7; RNAi; obesity; Phase 1/2a; tirzepatide; Zepbound; weight loss